While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

Sichun Yang, PhD, a member of Case CCC's Molecular Oncology Program, and Alberto Montero, MD, a Developmental Therapeutics Program member, are looking for patient advocates for a follow-up study to ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

A fast-rising form of breast cancer that's harder to detect on mammograms now makes up more than one in ten cases in the United States, according to a new report from the American Cancer Society (ACS) ...

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

Dr. Melvin Silverstein answers the question: 'What's Invasive Ductal Carcinoma?' — -- Question: What is invasive ductal carcinoma? Answer: Invasive ductal carcinoma is the most common type of ...

South Florida oncologists are seeing an alarming rise in a hard-to-detect breast cancer that is increasing at more than triple the rate of other breast cancers. Invasive lobular carcinoma, a subtype ...

Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC).

Changes in the degree of satisfaction and quality of life in breast cancer patients who are candidates for breast conservation but opted for mastectomy: A single-center prospective study. This is an ...